A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic Acid
NCT04811404 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL
Last updated 2022-10-14
Summary
This pilot study will ask whether omega three fatty acids have an antidepressant effect in bipolar depression by decreasing brain inflammation.
Conditions
Interventions
- DRUG
-
Ethyl Eicosapentaenoic Acid
Treatment will be for six weeks
Sponsors & Collaborators
-
New York State Psychiatric Institute
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-03-19
- Primary Completion
- 2022-07-01
- Completion
- 2022-07-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.
NCT06429722 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Bipolar Depression With Pentoxifylline
NCT04417049 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.
NCT05169710 ·Status: TERMINATED ·Phase: PHASE3
-
Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression
NCT00485771 ·Status: COMPLETED ·Phase: PHASE4
-
BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study
NCT02481245 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression
NCT00812058 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression
NCT00622245 ·Status: TERMINATED ·Phase: PHASE2
-
Omega-3 Fatty Acids in Bipolar Patients With a Low Omega-3 Index and Reduced Heart Rate Variability
NCT00891826 ·Status: COMPLETED ·Phase: NA
-
Prevention of Relapse & Recurrence of Bipolar Depression
NCT00961961 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression
NCT00771134 ·Status: TERMINATED ·Phase: PHASE2
-
18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder
NCT03902613 ·Status: COMPLETED ·Phase: PHASE4
-
Magnetic Resonance Imaging Study of Lisdexamfetamine for Bipolar Depression
NCT01051440 ·Status: TERMINATED ·Phase: PHASE4
-
PET and MRI Brain Imaging of Bipolar Disorder
NCT01880957 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder
NCT00490971 ·Status: COMPLETED ·Phase: PHASE3
-
Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging
NCT02473250 ·Status: COMPLETED ·Phase: PHASE4
-
Ceftriaxone in the Management of Bipolar Depression
NCT00566111 ·Status: TERMINATED ·Phase: NA
-
Pioglitazone for the Treatment of Bipolar Depression
NCT01717040 ·Status: TERMINATED ·Phase: PHASE4
-
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study
NCT00177567 ·Status: COMPLETED ·Phase: PHASE4
-
Trial of Ketamine and Lithium Therapy in Bipolar Depression
NCT01768767 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder
NCT00299715 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram
NCT00562861 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Depression, Obesity and Inflammatory Markers
NCT02765100 ·Status: COMPLETED ·Phase: NA
-
Treatment Study of Bipolar Depression
NCT00947791 ·Status: TERMINATED ·Phase: PHASE4
-
RU-486 in the Treatment of Bipolar Depression
NCT00359125 ·Status: WITHDRAWN ·Phase: PHASE2
-
Cytidine- and Creatine-Containing Drug in Treating Bipolar Depression
NCT01543139 ·Status: WITHDRAWN ·Phase: PHASE2